TOP TIERMARKET NEWSWIRE

News & sentiment

SUMMIT THERAPEUTICS (SMMT) — News & AI sentiment

SUMMIT THERAPEUTICS (SMMT) news roundup. 17 stories in the past week, 30 over 30 days. Average 30-day sentiment is 53.1/100. Recent insider activity (SEC Form 4, 90-day window): 5 purchases totalling $103.6M and 0 sales totalling $0 — net buying of $103.6M. No congressional trade disclosures in the last 90 days. Data shown on this page is delayed 4 hours. Real-time access — including the live wire, real-time alerts, the live S&P 500 heatmap, and the AI Top Trades long/short board — is available with a Top Tier Newswire Pro subscription.

Public view, delayed 4h. For real-time news, alerts, AI sentiment and the long/short AI Top Trades board:Open in the live terminal →

24h stories

0

7d stories

17

avg sentiment 48.9/100

30d stories

30

avg sentiment 53.1/100

Insider net (90d)

$103.6M

5 buys · 0 sells

Congress (90d)

0

0 buys · 0 sells

Latest stories on SMMT

Kuehn Law Encourages Investors of Summit Therapeutics Inc. to Contact Law Firm

PR Newswire34 · bearishgeneral

3d ago

SMMT Stock Heads For Third Straight Weekly Drop – Analyst Tempers Expectations From Initial Lung Cancer Trial Survival Data

Stocktwits News38 · neutralgeneral

6d ago

Stifel cuts Summit Therapeutics stock price target on timing concerns

Investing.com Analyst Ratings38 · neutralanalyst

6d ago

Cantor Fitzgerald reiterates Overweight on Summit Therapeutics stock

Investing.com Analyst Ratings61 · neutralanalyst

6d ago

At a glance: stocks gapping down premarket

Seeking Alpha34 · bearishgeneral

6d ago

Ivonescimab’s Consistent Survival Benefit Highlights Summit Therapeutics’ Progress—PDUFA Date Set for November 2026 July 24, 2026

MarketChameleon73 · bullishproduct/pr

6d ago

Summit Therapeutics Says Extended Follow-Up Reveals Stronger Survival Advantages with lead Cancer Drug

Yahoo Top73 · bullishproduct/pr

6d ago

Summit outlines November 14 FDA PDUFA date for ivonescimab BLA while planning HARMONi-3 PFS in 2H 2026

Seeking Alpha63 · neutralproduct/pr

6d ago

Summit Therapeutics Inc. (SMMT) Q2 2026 Earnings Call Transcript

Seeking Alpha50 · neutralearnings

6d ago

Summit Therapeutics Inc. 2026 Q2 - Results - Earnings Call Presentation

Seeking Alpha50 · neutralearnings

6d ago

Summit Therapeutics says cash crunch could impact its ability to continue

Seeking Alpha22 · bearishgeneral

6d ago

Summit Therapeutics Establishes $380 Million ATM Equity Program

TipRanks28 · bearishgeneral

6d ago

Summit Therapeutics Reports Ivonescimab Progress and Strong Cash

TipRanks56 · neutralproduct/pr

6d ago

Summit Therapeutics GAAP EPS of -$0.28 beats by $0.01

Seeking Alpha56 · neutralearnings

6d ago

Summit Therapeutics Inc. (SMMT) files 8-K

SEC 8-K50 · neutralgeneral

6d ago

Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2026 | SMMT Stock News

StockTitan56 · neutralearnings

6d ago

H.C. Wainwright reiterates Neutral stock rating on Summit Therapeutics

Investing.com Analyst Ratings50 · neutralanalyst

7d ago

Arcus Biosciences and Summit Therapeutics Enter Into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer | RCUS Stock News

StockTitan56 · neutralproduct/pr

Jul 22

Summit Therapeutics: 'Buy' On Ivonescimab's November PDUFA And Impressive Partner Data

Seeking Alpha63 · neutralanalyst

Jul 22

SMMT Stock Gains After Summit Reports Strong Lung Cancer Survival Results — Investors Await Q2 Earnings

Stocktwits News63 · neutralproduct/pr

Jul 22

Summit Therapeutics shares advance after updated Phase III cancer trial results (NASDAQ:SMMT)

InvestorsHub67 · bullishproduct/pr

Jul 22

Ivonescimab Plus Chemotherapy Achieves Consistent Survival Benefit for Western and Asian NSCLC Patients: Updated Phase III HARMONi Trial Data July 22, 2026

MarketChameleon73 · bullishproduct/pr

Jul 22

Summit updates survival data for Akeso-partnered lung cancer drug

Seeking Alpha38 · neutralproduct/pr

Jul 22

Summit Therapeutics Inc. (SMMT) files 8-K

SEC 8-K50 · neutralgeneral

Jul 22

Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase III HARMONi Study | SMMT Stock News

StockTitan73 · bullishproduct/pr

Jul 22

Open SMMT in the live Top Tier Newswire terminal for real-time stories, sentiment, insider + congress alerts, and the AI Top Trades long/short board.Start a 1-day free trial →